CCX140 is primarily researched for its potential therapeutic applications in treating metabolic and inflammatory diseases. It acts as a selective antagonist of the CCR2 receptor, which plays a key role in the recruitment of monocytes and macrophages to sites of inflammation. This mechanism makes it a promising candidate for addressing conditions such as diabetic nephropathy, where inflammation and immune cell infiltration contribute to disease progression. Additionally, CCX140 has been explored for its potential in managing atherosclerosis by reducing the accumulation of inflammatory cells in arterial plaques. Its ability to modulate immune responses also opens avenues for research in other chronic inflammatory and autoimmune disorders.